Instil Bio, Inc. (TIL): Total Assets
$203.52M
As of 2025-12-31
$197.71M
As of 2026-06-30
-25.0%
3-year compound annual growth
-8.6%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $203.52M | -22.8% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $263.57M | -19.1% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $325.63M | -32.5% | 2025-03-04, Balance as of period end |
| 2022-12-31 | $482.13M | -21.0% | 2024-03-21, Balance as of period end |
| 2021-12-31 | $609.98M | +91.2% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $319.01M | n/a | 2022-03-07, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | 2025-12-31 | $203.52M | -22.8% |
| Protara Therapeutics, Inc. (TARA) | 2025-12-31 | $209.47M | +15.4% |
| Neumora Therapeutics, Inc. (NMRA) | 2025-12-31 | $191.05M | -39.7% |
| Compass Therapeutics, Inc. (CMPX) | 2025-12-31 | $219.59M | +56.4% |
| Metagenomi Therapeutics, Inc. (MGX) | 2025-12-31 | $221.10M | -31.9% |
| enGene Therapeutics Inc. (ENGN) | 2025-10-31 | $221.47M | -28.8% |
| Editas Medicine, Inc. (EDIT) | 2025-12-31 | $186.53M | -45.4% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $186.08M | +11.8% |
| Century Therapeutics, Inc. (IPSC) | 2025-12-31 | $223.70M | -36.7% |
Compare TIL, TARA, NMRA, CMPX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗